Désiré Collen
Désiré Collen (born June 21, 1943 in Sint-Truiden ) is a Belgian medic and molecular biologist.
Collen received his doctorate in medicine from the Catholic University of Leuven in 1968 and in chemistry in 1974. He became a professor at the Catholic University of Leuven, where he has been professor at the Center for Vascular and Molecular Biology since 2002. He also heads the Transgenic Technology and Gene Therapy Department at the Flemish Institute for Biotechnology.
In 1979 he discovered the tissue-specific plasminogen activator (tPA), which was produced by Genentech using recombinant DNA technology from 1982 and which was a major advance in the treatment of thrombolysis (strokes, pulmonary embolisms).
In 1991 he founded the biotech company ThromboGenics. In 1998 he founded the startup financing company in Biotechnik Life Sciences Research Partners.
He has been involved in over 650 publications and over 20 patents.
In 1986 he received the Louis Jeantet Prize , the Francqui Prize in 1984 and the Artois-Baillet Latour Health Prize in 2005 . Since 1989 he has been a full member of the Academia Europaea .
Web links
References and comments
- ↑ A. Billiau, J. Edy, P. De Somer: Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta., Volume 29, 1977, pp. 194-201
- ↑ Press release ThromboGenics on the occasion of his resignation as Chairman in 2013
- ↑ Directory of members: Désiré Baron Collen. Academia Europaea, accessed on August 17, 2017 .
| personal data | |
|---|---|
| SURNAME | Collen, Désiré |
| BRIEF DESCRIPTION | Belgian physician and molecular biologist |
| DATE OF BIRTH | June 21, 1943 |
| PLACE OF BIRTH | Sint-Truiden |